CA2188185A1 - Slow-release matrix pellets and the production thereof - Google Patents
Slow-release matrix pellets and the production thereofInfo
- Publication number
- CA2188185A1 CA2188185A1 CA002188185A CA2188185A CA2188185A1 CA 2188185 A1 CA2188185 A1 CA 2188185A1 CA 002188185 A CA002188185 A CA 002188185A CA 2188185 A CA2188185 A CA 2188185A CA 2188185 A1 CA2188185 A1 CA 2188185A1
- Authority
- CA
- Canada
- Prior art keywords
- release matrix
- slow
- matrix pellets
- production
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011159 matrix material Substances 0.000 title abstract 2
- 239000008188 pellet Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003349 gelling agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000004014 plasticizer Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
- 229920003176 water-insoluble polymer Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Abstract
Disclosed are sustained-release matrix pellets of spherical to lenticular shape and uniform maximum diameter in the range of 0-5 to 4 mm, consisting of a) 0.1 to 87 wt % of at least one biologically active compound, b) 5 to 50 wt % of at least one water-insoluble polymer, c) 5-45 wt % of at least one lipophilic component as plasticizer for the b) polymer, d) 3 to 40 wt % of a natural or semisynthetic gelling agent, e) 0 to 50 wt% of one or more common formulation auxiliaries.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DEP4413350.2 | 1994-04-18 | ||
DE4413350A DE4413350A1 (en) | 1994-04-18 | 1994-04-18 | Retard matrix pellets and process for their production |
PCT/EP1995/001236 WO1995028147A1 (en) | 1994-04-18 | 1995-04-05 | Sustained-release matrix pellets and method for preparing them |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2188185A1 true CA2188185A1 (en) | 1995-10-26 |
CA2188185C CA2188185C (en) | 2005-06-07 |
Family
ID=6515707
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002188185A Expired - Lifetime CA2188185C (en) | 1994-04-18 | 1995-04-05 | Slow-release matrix pellets and the production thereof |
Country Status (23)
Country | Link |
---|---|
US (1) | US6290990B1 (en) |
EP (1) | EP0756480B1 (en) |
JP (1) | JP4099225B2 (en) |
KR (1) | KR100371885B1 (en) |
CN (1) | CN1131024C (en) |
AT (1) | ATE204747T1 (en) |
AU (1) | AU2256495A (en) |
BR (1) | BR9507328A (en) |
CA (1) | CA2188185C (en) |
CZ (1) | CZ301396A3 (en) |
DE (2) | DE4413350A1 (en) |
DK (1) | DK0756480T3 (en) |
ES (1) | ES2162635T3 (en) |
FI (1) | FI964175A (en) |
HU (1) | HU221981B1 (en) |
IL (1) | IL113316A (en) |
MX (1) | MXPA96004911A (en) |
NO (1) | NO313735B1 (en) |
NZ (1) | NZ284064A (en) |
PL (1) | PL317936A1 (en) |
PT (1) | PT756480E (en) |
RU (1) | RU2155031C2 (en) |
WO (1) | WO1995028147A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387401B2 (en) | 1995-08-25 | 2002-05-14 | Basf Aktiengesellschaft | Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process |
WO2002060384A2 (en) | 2001-01-30 | 2002-08-08 | Smithkline Beecham Plc. | Pharmaceutical formulation |
WO2005009380A2 (en) | 2003-07-21 | 2005-02-03 | Smith Kline Beecham P.L.C. | Pharmaceutical formulations |
WO2009087483A2 (en) | 2007-11-08 | 2009-07-16 | Glaxo Group Limited | Pharmaceutical formulations |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US5965161A (en) † | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
DE19539362A1 (en) * | 1995-10-23 | 1997-04-24 | Basf Ag | Process for the production of solid dosage forms |
DE19539360A1 (en) * | 1995-10-23 | 1997-04-24 | Basf Ag | Process for the production of solid dosage forms |
FR2748209B1 (en) * | 1996-05-06 | 1998-06-05 | Adir | PHARMACEUTICAL COMPOSITION BASED ON STABILIZED LIPOPHILIC MATRICES FOR THE CONTROLLED RELEASE OF ACTIVE INGREDIENTS |
DE19637082A1 (en) | 1996-09-12 | 1998-03-19 | Boehringer Mannheim Gmbh | Rapidly disintegrating pellets |
US8828432B2 (en) * | 1996-10-28 | 2014-09-09 | General Mills, Inc. | Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles |
FR2761605B1 (en) * | 1997-04-07 | 2001-02-23 | Prographarm Lab | MULTIPARTICULAR PHARMACEUTICAL FORM, ITS CONSTITUENT PARTICLES, METHOD AND PLANT FOR THEIR MANUFACTURE |
ATE438305T1 (en) * | 1998-03-23 | 2009-08-15 | Gen Mills Inc | ENCAPSULATION OF COMPONENTS IN EDIBLE PRODUCTS |
DE19842753A1 (en) | 1998-09-18 | 2000-03-23 | Bayer Ag | Multiple-unit retard oral dosage formulation having controlled release independent of agitation and food effect, containing particles of combination of drug and hydroxypropyl cellulose |
PL208550B1 (en) | 1999-07-30 | 2011-05-31 | Smithkline Beecham Plc | Multi−component pharmaceutical dosage form |
DE10045904B4 (en) * | 1999-10-01 | 2007-07-12 | Degussa Gmbh | alpha-lipoic acid (derivatives) containing sustained release form |
HU230828B1 (en) | 1999-10-29 | 2018-08-28 | Euro Celtique Sa | Controlled release hydrocodone formulations |
US10179130B2 (en) | 1999-10-29 | 2019-01-15 | Purdue Pharma L.P. | Controlled release hydrocodone formulations |
EP1175205B1 (en) * | 1999-11-12 | 2006-06-14 | Abbott Laboratories | Solid dispersion comprising ritonavir, fenofibrate or griseofulvin |
US7364752B1 (en) | 1999-11-12 | 2008-04-29 | Abbott Laboratories | Solid dispersion pharamaceutical formulations |
US8088060B2 (en) | 2000-03-15 | 2012-01-03 | Orbusneich Medical, Inc. | Progenitor endothelial cell capturing with a drug eluting implantable medical device |
US9522217B2 (en) | 2000-03-15 | 2016-12-20 | Orbusneich Medical, Inc. | Medical device with coating for capturing genetically-altered cells and methods for using same |
EP1272181A2 (en) * | 2000-04-13 | 2003-01-08 | Synthon B.V. | Modified release formulations containing a hypnotic agent |
DE10026698A1 (en) * | 2000-05-30 | 2001-12-06 | Basf Ag | Self-emulsifying active ingredient formulation and use of this formulation |
WO2002036099A1 (en) | 2000-10-30 | 2002-05-10 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
US7842308B2 (en) | 2001-01-30 | 2010-11-30 | Smithkline Beecham Limited | Pharmaceutical formulation |
US7883721B2 (en) | 2001-01-30 | 2011-02-08 | Smithkline Beecham Limited | Pharmaceutical formulation |
US6555581B1 (en) | 2001-02-15 | 2003-04-29 | Jones Pharma, Inc. | Levothyroxine compositions and methods |
US20030198671A1 (en) * | 2001-08-10 | 2003-10-23 | Franz G. Andrew | Levothyroxine compositions having unique plasma AUC properties |
DE10150938A1 (en) * | 2001-10-04 | 2003-04-24 | Frunol Delicia Gmbh | Pest control product in the form of lens-shaped granules, especially for controlling slugs and snails or rats and mice |
US20030165564A1 (en) * | 2001-10-29 | 2003-09-04 | Franz G. Andrew | Levothyroxine compositions having unique triiodothyronine Tmax properties |
US7700134B2 (en) * | 2002-01-17 | 2010-04-20 | The Regents Of The University Of Michigan | Prevention of cisplatin induced deafness |
US8128957B1 (en) | 2002-02-21 | 2012-03-06 | Valeant International (Barbados) Srl | Modified release compositions of at least one form of tramadol |
US20050182056A9 (en) * | 2002-02-21 | 2005-08-18 | Seth Pawan | Modified release formulations of at least one form of tramadol |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
RU2336863C2 (en) * | 2002-06-27 | 2008-10-27 | Цилаг Аг | Ball shaped medications in form of pellets |
CA2491572C (en) * | 2002-07-05 | 2010-03-23 | Collegium Pharmaceutical, Inc. | Abuse-deterrent pharmaceutical compositions of opiods and other drugs |
US8840928B2 (en) | 2002-07-05 | 2014-09-23 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
AU2003268078A1 (en) * | 2002-08-10 | 2004-02-25 | King Pharmaceuticals, Inc. | Levothyroxine compositions and methods |
DE10247037A1 (en) * | 2002-10-09 | 2004-04-22 | Abbott Gmbh & Co. Kg | Solid, rapid release dosage form, especially for sparingly soluble drugs, obtained by forming and cooling softened, shapable mixture of crosslinked non-thermoplastic carrier, adjuvant and active agent |
KR20040043589A (en) * | 2002-11-19 | 2004-05-24 | 경동제약 주식회사 | Slow releasable drugs containing cefarclor as a effective ingredient and preparing method thereof |
SI21353A (en) * | 2002-11-27 | 2004-06-30 | Lek farmacevtska družba, d.d. | Pellet-containing anhydrous liquids and process of their preparation |
ES2208123A1 (en) * | 2002-11-29 | 2004-06-01 | Laboratorios Del Dr. Esteve, S.A. | Use of 2,5-dihydroxybenzenesulfonic compounds for the treatment of disorders based on an impairment of no production and/or of regulation of edhf function |
ES2208124B1 (en) * | 2002-11-29 | 2005-10-01 | Laboratorios Del Dr. Esteve, S.A. | USE OF 2,5-DIHYDROXIBENCENOSULFONIC COMPOUNDS FOR THE MANUFACTURE OF A MEDICINAL PRODUCT. |
DK1590144T3 (en) * | 2002-12-10 | 2015-11-09 | Nortec Dev Ass | Process for preparing biologically active formulations |
JP2006516969A (en) * | 2003-01-23 | 2006-07-13 | アモレパシフィック コーポレーション | Sustained release preparation and method for producing the same |
US20070059358A1 (en) * | 2003-07-02 | 2007-03-15 | Tianjin Tasly Pharmaceutical Co., Ltd., China | Matrix adjuvants and the drop pills prepared with them |
DE102005005446A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Break-resistant dosage forms with sustained release |
US8075872B2 (en) | 2003-08-06 | 2011-12-13 | Gruenenthal Gmbh | Abuse-proofed dosage form |
DE10336400A1 (en) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Anti-abuse dosage form |
US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
DE102004032051A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Process for the preparation of a secured against misuse, solid dosage form |
DE10361596A1 (en) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US8377952B2 (en) | 2003-08-28 | 2013-02-19 | Abbott Laboratories | Solid pharmaceutical dosage formulation |
US8025899B2 (en) | 2003-08-28 | 2011-09-27 | Abbott Laboratories | Solid pharmaceutical dosage form |
GB0403098D0 (en) * | 2004-02-12 | 2004-03-17 | Euro Celtique Sa | Extrusion |
TWI350762B (en) * | 2004-02-12 | 2011-10-21 | Euro Celtique Sa | Particulates |
PE20060003A1 (en) | 2004-03-12 | 2006-03-01 | Smithkline Beecham Plc | POLYMERIC PHARMACEUTICAL FORMULATION FOR INJECTION MOLDING |
PT1765292T (en) | 2004-06-12 | 2017-12-29 | Collegium Pharmaceutical Inc | Abuse-deterrent drug formulations |
DE102004032049A1 (en) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Anti-abuse, oral dosage form |
EP1771159A4 (en) * | 2004-07-22 | 2009-04-29 | Amorepacific Corp | Sustained-release preparations containing topiramate and the producing method thereof |
US20080108750A1 (en) * | 2004-12-27 | 2008-05-08 | Toru Terada | Thermoplastic Resin Composition |
TW200630401A (en) * | 2004-12-27 | 2006-09-01 | Kaneka Corp | Process for producing aggregated latex particle |
JP5078361B2 (en) * | 2004-12-27 | 2012-11-21 | 株式会社カネカ | Thermoplastic resin composition |
DE102005005449A1 (en) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Process for producing an anti-abuse dosage form |
US7803413B2 (en) * | 2005-10-31 | 2010-09-28 | General Mills Ip Holdings Ii, Llc. | Encapsulation of readily oxidizable components |
US20070184163A1 (en) * | 2006-02-07 | 2007-08-09 | International Flavors, & Fragrances Inc. | Non-hygroscopic flavor particles |
US20090169617A1 (en) * | 2006-04-26 | 2009-07-02 | Panagiotis Keramidas | Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US8445018B2 (en) | 2006-09-15 | 2013-05-21 | Cima Labs Inc. | Abuse resistant drug formulation |
JP5452236B2 (en) * | 2007-03-02 | 2014-03-26 | ファーナム・カンパニーズ・インコーポレーテッド | Sustained release composition using wax-like substance |
DE102007011485A1 (en) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Dosage form with more difficult abuse |
WO2009088319A1 (en) * | 2007-12-29 | 2009-07-16 | Physics Depertment M.V. Lomonosov Moscow State University | Magnetic polymer granules and a method for forming a locking gel plug |
CA2710988A1 (en) * | 2007-12-29 | 2009-07-16 | Physics Department M.V. Lomonosov Moscow State University | Magnetic polymer pellets and their application methods |
RU2493830C2 (en) | 2008-01-25 | 2013-09-27 | Грюненталь Гмбх | Drug form |
KR101094231B1 (en) * | 2008-02-18 | 2011-12-14 | 하나제약 주식회사 | Sustained release solid formulations and methods of manufacturing the same |
AU2009243681B2 (en) | 2008-05-09 | 2013-12-19 | Grunenthal Gmbh | Process for the preparation of an intermediate powder formulation and a final solid dosage form under usage of a spray congealing step |
MX2011000825A (en) * | 2008-07-22 | 2011-02-25 | Gen Mills Inc | Fruit products containing omega-3 fatty acids. |
US20100310728A1 (en) * | 2009-06-05 | 2010-12-09 | General Mills, Inc. | Encapsulated omega-3 fatty acids for baked goods production |
EP2997965B1 (en) | 2009-07-22 | 2019-01-02 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opioids |
PL2456427T3 (en) | 2009-07-22 | 2015-07-31 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
CA2994873A1 (en) | 2009-12-02 | 2011-06-09 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
CA2798702A1 (en) | 2010-05-11 | 2011-11-17 | Cima Labs Inc. | Alcoholresistant metoprolol-containing extended-release oral dosage forms |
MX2013002377A (en) | 2010-09-02 | 2013-04-29 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt. |
TWI516286B (en) | 2010-09-02 | 2016-01-11 | 歌林達股份有限公司 | Tamper resistant dosage form comprising an anionic polymer |
DE102011018403A1 (en) * | 2011-04-21 | 2012-10-25 | Automatik Plastics Machinery Gmbh | Process for the preparation of pharmaceutical products from a melt material |
BR112014001091A2 (en) | 2011-07-29 | 2017-02-14 | Gruenenthal Gmbh | tamper resistant tablet that provides immediate release of the drug |
LT2736495T (en) | 2011-07-29 | 2017-11-10 | Grünenthal GmbH | Tamper-resistant tablet providing immediate drug release |
BR112014019988A8 (en) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | BREAK-RESISTANT DOSAGE FORM COMPRISING A PHARMACOLOGICALLY ACTIVE COMPOUND AND AN ANIONIC POLYMER |
AR090695A1 (en) | 2012-04-18 | 2014-12-03 | Gruenenthal Gmbh | PHARMACEUTICAL DOSAGE FORM RESISTANT TO ADULTERATION AND RESISTANT TO IMMEDIATE RELEASE OF DOSE |
US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
JP6466417B2 (en) | 2013-05-29 | 2019-02-06 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | A tamper-resistant dosage form with a bimodal release profile |
CA2907950A1 (en) | 2013-05-29 | 2014-12-04 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
US10154971B2 (en) | 2013-06-17 | 2018-12-18 | Adamas Pharma, Llc | Methods of administering amantadine |
RU2535049C1 (en) * | 2013-07-11 | 2014-12-10 | Общество с ограниченной ответственностью "КОМПАНИЯ "ДЕКО" | Method of producing stabilised drotaverine hydrochloride substance |
MX368846B (en) | 2013-07-12 | 2019-10-18 | Gruenenthal Gmbh | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer. |
US20150118300A1 (en) | 2013-10-31 | 2015-04-30 | Cima Labs Inc. | Immediate Release Abuse-Deterrent Granulated Dosage Forms |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
CA2947786A1 (en) | 2014-05-12 | 2015-11-19 | Grunenthal Gmbh | Tamper resistant immediate release capsule formulation comprising tapentadol |
EP3148512A1 (en) | 2014-05-26 | 2017-04-05 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
JP2018526414A (en) | 2015-09-10 | 2018-09-13 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | Protection against oral overdose with abuse-inhibiting immediate release formulations |
US9737530B1 (en) | 2016-06-23 | 2017-08-22 | Collegium Pharmaceutical, Inc. | Process of making stable abuse-deterrent oral formulations |
CN111372578A (en) | 2017-08-24 | 2020-07-03 | 阿达玛斯药物有限责任公司 | Amantadine compositions, methods of making and using the same |
EP3965733A4 (en) | 2019-05-07 | 2023-01-11 | Clexio Biosciences Ltd. | Abuse-deterrent dosage forms containing esketamine |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL297357A (en) | 1962-08-31 | |||
US4421736A (en) * | 1982-05-20 | 1983-12-20 | Merrel Dow Pharmaceuticals Inc. | Sustained release diethylpropion compositions |
FR2581541B1 (en) * | 1985-05-09 | 1988-05-20 | Rhone Poulenc Sante | NOVEL PHARMACEUTICAL COMPOSITIONS FOR THE EXTENDED RELEASE OF AN ACTIVE INGREDIENT AND THEIR PREPARATION METHOD |
DE3612211A1 (en) | 1986-04-11 | 1987-10-15 | Basf Ag | CONTINUOUS TABLET METHOD |
DE3612212A1 (en) | 1986-04-11 | 1987-10-15 | Basf Ag | METHOD FOR PRODUCING SOLID PHARMACEUTICAL FORMS |
US5326572A (en) * | 1989-03-23 | 1994-07-05 | Fmc Corporation | Freeze-dried polymer dispersions and the use thereof in preparing sustained-release pharmaceutical compositions |
US4983399A (en) * | 1989-10-18 | 1991-01-08 | Eastman Kodak Company | Direct compression carrier composition |
WO1993007859A1 (en) * | 1991-10-23 | 1993-04-29 | Warner-Lambert Company | Novel pharmaceutical pellets and process for their production |
DE4138513A1 (en) * | 1991-11-23 | 1993-05-27 | Basf Ag | SOLID PHARMACEUTICAL RETARD FORM |
-
1994
- 1994-04-18 DE DE4413350A patent/DE4413350A1/en not_active Withdrawn
-
1995
- 1995-04-05 PT PT95915844T patent/PT756480E/en unknown
- 1995-04-05 WO PCT/EP1995/001236 patent/WO1995028147A1/en active IP Right Grant
- 1995-04-05 JP JP52666695A patent/JP4099225B2/en not_active Expired - Fee Related
- 1995-04-05 RU RU96122469/14A patent/RU2155031C2/en active
- 1995-04-05 DK DK95915844T patent/DK0756480T3/en active
- 1995-04-05 AU AU22564/95A patent/AU2256495A/en not_active Abandoned
- 1995-04-05 CZ CZ963013A patent/CZ301396A3/en unknown
- 1995-04-05 AT AT95915844T patent/ATE204747T1/en active
- 1995-04-05 CN CN95192933A patent/CN1131024C/en not_active Expired - Lifetime
- 1995-04-05 BR BR9507328A patent/BR9507328A/en not_active Application Discontinuation
- 1995-04-05 PL PL95317936A patent/PL317936A1/en unknown
- 1995-04-05 NZ NZ284064A patent/NZ284064A/en unknown
- 1995-04-05 MX MXPA96004911A patent/MXPA96004911A/en active IP Right Grant
- 1995-04-05 CA CA002188185A patent/CA2188185C/en not_active Expired - Lifetime
- 1995-04-05 KR KR1019960705854A patent/KR100371885B1/en not_active IP Right Cessation
- 1995-04-05 ES ES95915844T patent/ES2162635T3/en not_active Expired - Lifetime
- 1995-04-05 HU HU9602878A patent/HU221981B1/en active IP Right Grant
- 1995-04-05 EP EP95915844A patent/EP0756480B1/en not_active Expired - Lifetime
- 1995-04-05 DE DE59509563T patent/DE59509563D1/en not_active Expired - Lifetime
- 1995-04-11 IL IL11331695A patent/IL113316A/en not_active IP Right Cessation
- 1995-04-15 US US08/727,666 patent/US6290990B1/en not_active Expired - Lifetime
-
1996
- 1996-10-17 NO NO19964410A patent/NO313735B1/en not_active IP Right Cessation
- 1996-10-17 FI FI964175A patent/FI964175A/en unknown
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6387401B2 (en) | 1995-08-25 | 2002-05-14 | Basf Aktiengesellschaft | Use of lipids as adjuvents in the production of solid medicinal forms by the melt extrusion process |
WO2002060384A2 (en) | 2001-01-30 | 2002-08-08 | Smithkline Beecham Plc. | Pharmaceutical formulation |
WO2002060385A2 (en) | 2001-01-30 | 2002-08-08 | Smithkline Beecham Plc. | Pharmaceutical formulation |
EP2366384A2 (en) | 2001-01-30 | 2011-09-21 | Pfizer Inc. | Pharmaceutical formulation |
EP2366383A2 (en) | 2001-01-30 | 2011-09-21 | Pfizer Inc. | Pharmaceutical formulation |
EP2366382A2 (en) | 2001-01-30 | 2011-09-21 | Pfizer Inc. | Pharmaceutical formulation |
WO2005009380A2 (en) | 2003-07-21 | 2005-02-03 | Smith Kline Beecham P.L.C. | Pharmaceutical formulations |
WO2009087483A2 (en) | 2007-11-08 | 2009-07-16 | Glaxo Group Limited | Pharmaceutical formulations |
Also Published As
Publication number | Publication date |
---|---|
US6290990B1 (en) | 2001-09-18 |
JP4099225B2 (en) | 2008-06-11 |
RU2155031C2 (en) | 2000-08-27 |
KR970702028A (en) | 1997-05-13 |
NO964410L (en) | 1996-12-17 |
NZ284064A (en) | 1998-03-25 |
FI964175A0 (en) | 1996-10-17 |
WO1995028147A1 (en) | 1995-10-26 |
DK0756480T3 (en) | 2001-10-08 |
PT756480E (en) | 2002-02-28 |
DE4413350A1 (en) | 1995-10-19 |
PL317936A1 (en) | 1997-04-28 |
FI964175A (en) | 1996-12-16 |
ES2162635T3 (en) | 2002-01-01 |
IL113316A (en) | 1999-12-31 |
MXPA96004911A (en) | 2004-08-19 |
EP0756480B1 (en) | 2001-08-29 |
CA2188185C (en) | 2005-06-07 |
IL113316A0 (en) | 1995-07-31 |
HU9602878D0 (en) | 1996-12-30 |
BR9507328A (en) | 1997-09-30 |
HUT75161A (en) | 1997-04-28 |
NO313735B1 (en) | 2002-11-25 |
KR100371885B1 (en) | 2003-04-10 |
CN1147764A (en) | 1997-04-16 |
EP0756480A1 (en) | 1997-02-05 |
HU221981B1 (en) | 2003-03-28 |
AU2256495A (en) | 1995-11-10 |
NO964410D0 (en) | 1996-10-17 |
ATE204747T1 (en) | 2001-09-15 |
DE59509563D1 (en) | 2001-10-04 |
CN1131024C (en) | 2003-12-17 |
JPH09511992A (en) | 1997-12-02 |
CZ301396A3 (en) | 1997-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2188185A1 (en) | Slow-release matrix pellets and the production thereof | |
EP0744942B1 (en) | Controlled release hydrogel formulation | |
JP2527432B2 (en) | Long-acting drug delivery-matrix system | |
US5169645A (en) | Directly compressible granules having improved flow properties | |
RU2204249C2 (en) | Homogeneous mixture of pesticide pellets | |
CA2312710A1 (en) | Sustained release formulation containing three different types of polymers and tablet formed therefrom | |
CA2190882A1 (en) | The production of active substance compositions in the form of a solid solution of the active substance in a polymer matrix, and active substance compositions produced by this process | |
HK1010694A1 (en) | microencapsulated 1,2-benzazoles. | |
CA2118584A1 (en) | Fatty acid terminated polyanhydrides | |
AU5118990A (en) | Compositions for the sustained-release of chlorhexidine | |
IE881195L (en) | Ibuprofen sustained release matrix | |
EP0871435A4 (en) | Sustained release formulation containing three different types of polymers | |
EP0103387A3 (en) | Long-acting matrix tablet formulations | |
CA2157323A1 (en) | Gepirone dosage form | |
IE870064L (en) | Sustained release capsule | |
CA2178592A1 (en) | Long-acting injection suspensions and a process for their preparation | |
CA2244243A1 (en) | Chemically stable, insecticidally active phosphoroamidothioate pellet compositions and methods for their manufacture | |
AU2697100A (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
RU95109898A (en) | Method of producing a solid preparation for protection of cultivated plants, and solid preparation | |
CA2006184A1 (en) | Prolonged release composition based on trimebutine and process for the preparation thereof | |
CA2209673A1 (en) | Solid medicament form with active agent distributed in polymer material | |
HRP20020071B1 (en) | Pharmaceutical composition and preparation thereof | |
AU1442095A (en) | Biologically active agent encapsulated in biodegradable starch/polymer matrices | |
AU589254B2 (en) | Slow release formulations | |
CA2216371A1 (en) | Novel "burst-free" sustained release poly-(lactide/glycolide) microspheres |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20150407 |